Virios Therapeutics, Inc. (VIRI)
After hours:
| Previous Close | 0.4207 |
| Open | 0.4220 |
| Bid | 0.3010 x 200 |
| Ask | 0.5382 x 200 |
| Day's Range | 0.4103 - 0.4339 |
| 52 Week Range | 0.2790 - 2.4200 |
| Volume | |
| Avg. Volume | 298,167 |
| Market Cap | 7.925M |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings Date | Mar 18, 2024 - Apr 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.20 |
GlobeNewswireVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30
- GlobeNewswire
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms – ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a develo
- GlobeNewswire
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023. Key Highlights and Upcoming Milestones Virios received written communication from the Food and Drug Administration (“FDA”
